How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,009 results for

Systemic Lupus Erythematosus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Prediction of fetal loss in Chinese pregnant patients with systemic lupus erythematosus: a retrospective cohort study. (PubMed)

Prediction of fetal loss in Chinese pregnant patients with systemic lupus erythematosus: a retrospective cohort study. To develop a predictive model for fetal loss in women with systemic lupus erythematosus (SLE).A retrospective cohort study.Data were collected in a tertiary medical centre, located in Shanghai, China, from September 2011 to May 2017.338 pregnancies with SLE were analysed retrospectively. Cases of multiple pregnancy and those in which artificial abortion was performed

Full Text available with Trip Pro

2019 BMJ open

102. Point-of-Care Ultrasound to Identify the Source of Dyspnea in a Patient With Systemic Lupus Erythematosus. (PubMed)

Point-of-Care Ultrasound to Identify the Source of Dyspnea in a Patient With Systemic Lupus Erythematosus. Point-of-care ultrasound can be used to help identify the source of dyspnea in patients presenting to the emergency department. We present a case of an adolescent girl with a history of systemic lupus erythematosus presenting to the emergency department with chest pain and dyspnea and found to have both pleural and pericardial effusions on point-of-care ultrasound.

2019 Pediatric Emergency Care

103. Roseomonas mucosa infective endocarditis in patient with systemic lupus erythematosus: case report and review of literature. (PubMed)

Roseomonas mucosa infective endocarditis in patient with systemic lupus erythematosus: case report and review of literature. Roseomonas mucosa, as a Gram-negative coccobacilli, is an opportunistic pathogen that has rarely been reported in human infections. Here we describe a case of bacteremia in an infective endocarditis patient with systemic lupus erythematosus (SLE).A 44-year-old female patient with SLE suffered bacteremia caused by Roseomonas mucosa complicated with infective endocarditis

Full Text available with Trip Pro

2019 BMC Infectious Diseases

104. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. (PubMed)

Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. European League Against Rheumatism and are jointly supporting multiphase development of systemic lupus erythematosus (SLE) classification criteria based on weighted criteria and a continuous probability scale. Prior steps included item generation, item reduction and hierarchical organisation of candidate criteria using an evidence-based approach. Our objectives were to determine

2019 Annals of the Rheumatic Diseases

105. The American College of Rheumatology Provisional criteria for clinically relevant improvement in children & adolescents with childhood-onset systemic lupus erythematosus. (PubMed)

The American College of Rheumatology Provisional criteria for clinically relevant improvement in children & adolescents with childhood-onset systemic lupus erythematosus. To develop a Childhood Lupus Improvement Index (CHILI) as a tool to measure response to therapy in childhood-onset systemic lupus erythematosus (cSLE), with focus on clinically relevant improvement (CRIcSLE ).Pediatric nephrology and rheumatology subspecialists (n=213) experienced in cSLE management were invited to define (...) CRIcSLE and rate a total of 433 unique patient-profiles for the presence/absence of CRIcSLE . Patient-profiles included the cSLE core response variables [cSLE-CRVs: global assessment of patient well-being (Patient-global), physician assessment of cSLE activity (MD-global), disease activity index score (here: Systemic Lupus Erythematosus Disease Activity Index), urine protein-to-creatinine ratio (UPCR), Child Health Questionnaire physical summary score (CHQ-PhS)]. Percentage and absolute changes

2019 Arthritis care & research

106. PLD4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes. (PubMed)

PLD4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes. Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterised by autoantibody production and widespread inflammation damaging many organs. Previous genome-wide association studies (GWASs) have revealed over 80 genetic determinants of SLE, but they collectively explain a fraction of the heritability, and only a few were proven in vivo for the involvement in SLE. We

2019 Annals of the Rheumatic Diseases

107. Systemic lupus erythematosus in pregnancy: high risk, high reward. (PubMed)

Systemic lupus erythematosus in pregnancy: high risk, high reward. The aim of this study was to describe risks of systemic lupus erythematosus (SLE) in pregnancy and the importance of preconception counselling, medication optimization and close surveillance.Advances in care for pregnant patients with SLE have led to improved obstetric outcomes, but maternal and foetal risks continue to be elevated. Conception during periods of disease quiescence and continuation of most medications decrease (...) adverse pregnancy outcomes. Hydroxychloroquine (HCQ) appears protective against flares in pregnancy, neonatal congenital heart block and preterm birth.SLE in pregnancy confers increased maternal and foetal risks, including disease flares, preeclampsia, preterm birth, foetal growth restriction, neonatal lupus erythematosus (NLE) and congenital heart block. Disease control on an effective medication regimen mitigates many of these risks, but pregnancy in women with SLE remains a high-risk condition

2019 Current Opinion in Obstetrics and Gynecology

108. Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus. (PubMed)

Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus. Composite scores of cardiovascular (CV) risk factors underestimate the CV risk in patients with systemic lupus erythematosus (SLE). Carotid artery ultrasound (US) was found useful in identifying high CV-risk patients with inflammatory arthritis. We assessed the effect of carotid US assessments on the CV risk stratification of patients with SLE.This cross (...) -sectional study included 276 patients with SLE. These indices were measured: lipid profile, Systematic COronary Risk Evaluation (SCORE) risk calculation, and disease activity (SLE Disease Activity Index), severity (Katz), and damage [Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology Damage Index]. Carotid plaques were assessed by US. A multivariable regression analysis, adjusted for classic CV-related factors, was performed to evaluate how risk reclassification

2019 Journal of Rheumatology

109. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. (PubMed)

Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. In cross-sectional studies, elevated osteopontin (OPN) levels have been proposed to reflect, and/or precede, progressive organ damage and disease severity in systemic lupus erythematosus (SLE). We aimed, in a cohort of patients with recent-onset SLE, to determine whether raised serum OPN levels precede damage and/or are associated with disease activity or certain (...) disease phenotypes.We included 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who had 5 years of followup data available. All patients fulfilled the 1997 American College of Rheumatology (ACR) criteria. Baseline sera from patients and from age- and sex-matched population-based controls were analyzed for OPN using ELISA. Disease activity and damage were assessed at each annual followup visit using the SLE Disease Activity Index 2000 (SLEDAI-2K

Full Text available with Trip Pro

2019 Journal of Rheumatology

110. Epidemiologic Profile of Erectile Dysfunction in Patients with Systemic Lupus Erythematosus: The Latin American Landscape. (PubMed)

Epidemiologic Profile of Erectile Dysfunction in Patients with Systemic Lupus Erythematosus: The Latin American Landscape. The aim of this study was to describe the prevalence of erectile dysfunction (ED), as well as associated demographic and clinical features, in men with systemic lupus erythematosus (SLE), by means of a systematic, standardized evaluation.We performed a transversal study in 8 tertiary care centers in Latin America. We included male patients ≥ 16 years who fulfilled ≥ 4 (...) was 69%. Mean age in that group was 36.3 ± 1.03 years. Among SLE patients with and without ED, these factors were significantly different: the presence of persistent lymphopenia (p = 0.006), prednisone dose (9.3 ± 1.2 vs 5.3 ± 1.3 mg, p = 0.026), and the Systemic Lupus International Collaborating Clinics damage score (1.25 ± 0.14 vs 0.8 ± 0.16 points, p = 0.042). Independent risk factors for ED in patients with SLE were persistent lymphopenia (OR 2.79, 95% CI 1.37-5.70, p = 0.001) and corticosteroid

2019 Journal of Rheumatology

111. Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view. (PubMed)

Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view. Systemic Lupus Erythematosus (SLE) is a connective tissue disease that involves multiple organs. Ocular structures and visual pathways can be affected in SLE because of disease-related eye involvement or drug toxicity. All the part of the eye may be interested with an external, anterior involvement, responsible of the dry eye disease, or posterior (retina) and neuro-ophtalmic manifestations. Retinopathy in SLE

2019 Autoimmunity reviews

112. Mechanisms of action and historical facts on the use of intravenous immunoglobulins in systemic lupus erythematosus. (PubMed)

Mechanisms of action and historical facts on the use of intravenous immunoglobulins in systemic lupus erythematosus. The current existing therapies for severe cases of systemic lupus erythematosus (SLE) patients are still limited. Intravenous immunoglobulin (IVIGs), which are purified from the plasma of thousands of healthy human donors, have been profiled as efficacious and life-saving options for SLE patients refractory to conventional therapy. The specific mechanism of action by which IVIGs

2019 Autoimmunity reviews

113. Human Low-Affinity IgG Receptor FcγRIIA Polymorphism H131R Associates with Subclinical Atherosclerosis and Increased Platelet Activity in Systemic Lupus Erythematosus. (PubMed)

Human Low-Affinity IgG Receptor FcγRIIA Polymorphism H131R Associates with Subclinical Atherosclerosis and Increased Platelet Activity in Systemic Lupus Erythematosus. Essentials Systemic lupus erythematosus (SLE) patients are at increased risk for premature CVD. Platelet activity, vascular dysfunction and carotid artery plaque are associated with FcγRIIA genotype in SLE. FcγRIIA genotype was not associated with platelet activity or carotid plaque in healthy controls. FcγRIIA represents a link (...) that connects platelet activity, vascular health and CVD in SLE. SUMMARY: Background Systemic lupus erythematosus (SLE) is a complex autoimmune disease associated with an elevated risk of premature cardiovascular disease. Platelets express receptors contributing to inflammation and immunity, including FcγRIIA, the low affinity receptor of the Fc portion of IgG antibodies. The variation at a single amino acid substitution, H131R, in the extracellular binding domain alters the affinity for IgG, which may

2019 Journal of Thrombosis and Haemostasis

114. Long-Term Prognosis of Patients with Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension: CSTAR-PAH Cohort Study. (PubMed)

Long-Term Prognosis of Patients with Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension: CSTAR-PAH Cohort Study. This study aimed to identify the long-term clinical outcomes and prognostic factors of patients with systemic lupus erythematosus (SLE)-associated pulmonary arterial hypertension (PAH) confirmed by right heart catheterisation.A multicentre prospective cohort of SLE-associated PAH was established. Baseline and follow-up records were collected. The primary end

2019 European Respiratory Journal

115. Trichoscopic signs in systemic lupus erythematosus: a comparative study with 109 patients and 305 healthy controls. (PubMed)

Trichoscopic signs in systemic lupus erythematosus: a comparative study with 109 patients and 305 healthy controls. Hair and scalp involvement in systemic lupus erythematosus (SLE) can manifest as scarring alopecia, non-scarring alopecia or scalp/hair shaft changes without apparent hair loss. While trichoscopic signs in chronic cutaneous lupus are well established, data on SLE patients with normal-looking or non-scarring scalp are limited.To investigate trichoscopic features of SLE patients (...) without chronic cutaneous scalp lesions and compare the findings with normal controls, as well as determine which feature associates with systemic disease. Furthermore, we aim to explore different clinical presentations of the scalp in SLE patients and their association with disease activity.Trichoscopic photographs were taken from patients and healthy controls and evaluated by one blinded hair specialist. For SLE patients, their clinical presentations and evaluations for cutaneous, extracutaneous

2019 Journal of the European Academy of Dermatology and Venereology

116. Metabolic and structural skeletal muscle health in systemic lupus erythematosus related fatigue: a multi-modal magnetic resonance imaging study. (PubMed)

Metabolic and structural skeletal muscle health in systemic lupus erythematosus related fatigue: a multi-modal magnetic resonance imaging study. This study aimed to investigate the potential structural and metabolic role of skeletal muscle in SLE related fatigue.A case control, multi-modal MRI study was conducted. Cases were inactive SLE patients who reported chronic fatigue. Controls were age/sex matched healthy members of the general population. Participants were clinically characterised

2019 Arthritis care & research

117. Objectively-assessed foot and ankle characteristics in people with systemic lupus erythematosus: a comparison with age- and sex-matched controls. (PubMed)

Objectively-assessed foot and ankle characteristics in people with systemic lupus erythematosus: a comparison with age- and sex-matched controls. To objectively identify foot and ankle characteristics in people with SLE compared to age- and sex-matched controls.54 SLE and 56 control participants attended a study visit designed to comprehensively assess the foot and ankle. Objectively-assessed foot characteristics included muscle strength, joint motion, foot posture, foot problems, protective

Full Text available with Trip Pro

2019 Arthritis care & research

118. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. (PubMed)

Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. The objective of this study is to evaluate the efficacy and safety of bortezomib for treating systemic lupus erythematosus (SLE), in patients whose disease activity could not be controlled.Fourteen SLE patients with persistent disease activity were selected, who required prednisolone doses of >10 mg/d despite concomitant

2019 Modern Rheumatology

119. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative

European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative Childhood-onset systemic lupus erythematosus (cSLE) is a rare, multisystem and potentially life-threatening autoimmune disorder with significant associated morbidity. Evidence-based guidelines are sparse and management is often based on clinical expertise. SHARE (Single Hub and Access point for paediatric Rheumatology in Europe) was launched to optimise (...) and disseminate management regimens for children and young adults with rheumatic diseases like cSLE. Here, we provide evidence-based recommendations for diagnosis and treatment of cSLE. In view of extent and complexity of cSLE and its various manifestations, recommendations for lupus nephritis and antiphospholipid syndrome will be published separately. Recommendations were generated using the EULAR (European League Against Rheumatism) standard operating procedure. An expert committee consisting of paediatric

Full Text available with Trip Pro

2017 EvidenceUpdates

120. Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study

Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study To examine the association between the use of statins and the risk of systemic lupus erythematosus (SLE) with focus on describing the patterns of risks over time.A population-based cohort study using the UK Clinical Practice Research Datalink.All patients aged 40 years or older who had at least one prescription of statins during the period 1995-2009 were selected and matched by age, sex

2017 EvidenceUpdates

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>